Pilot or Two-Stage [Design Issues]

posted by Ken Peh – Malaysia, 2013-02-18 19:19 (4871 d 01:25 ago) – Posting: # 10052
Views: 8,263

Dear Helmut,

❝ The 30years old paper does not help. After 5mg in five (!) subjects CVtotal of Cmax 93% and of AUCt 51%… You need CVintra from a cross-over study.


Understood. TQVM.

❝ IMHO you have two options:

Perform a pilot study which will (after drop-outs) > the minimum sample size in your regulation (Malaysia: 12). State in the protocol that if you are able to show BE already in the pilot the study will act as the pivotal study.


Do you mean if we use 20 subjects (>12) and able to show BE although the power is less than 80%, we can switch from pilot to pivotal ? How to justify to the regulatory agency on this ?

Perform a Two-Stage Sequential Design (see e.g., this presentation). Ask your authority whether such a design is acceptable. The Malaysian GL from 2000 of course does not cover such a design.


Yes, the new ASEAN guideline addresses this. Thank you for the presentation. Will digest the information.

Highly appreciate your kind assistance.

Best Regards,
Ken

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
114 visitors (0 registered, 114 guests [including 11 identified bots]).
Forum time: 21:45 CEST (Europe/Vienna)

Science is simply common sense at its best that is,
rigidly accurate in observation, and
merciless to fallacy in logic.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5